214 related articles for article (PubMed ID: 35472699)
21. [Mode of action, new targets and potential biomarkers in modern immunotherapy].
Bedke J; Stühler V; Todenhöfer T; Stenzl A
Urologe A; 2018 Nov; 57(11):1301-1308. PubMed ID: 30350128
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
Mann SA; Lopez-Beltran A; Massari F; Pili R; Fiorentino M; Koch MO; Kaimakliotis HZ; Wang L; Scarpelli M; Ciccarese C; Moch H; Montironi R; Cheng L
Curr Drug Metab; 2017 Oct; 18(8):700-711. PubMed ID: 28524003
[TBL] [Abstract][Full Text] [Related]
23. [Systemic immune checkpoint inhibition : A promising treatment for urological tumors?].
Roos FC; Becker C; Stope MB; Tsaur I;
Urologe A; 2018 May; 57(5):583-590. PubMed ID: 29569115
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
Bigot F; Bonnet C; Massard C
Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
[TBL] [Abstract][Full Text] [Related]
25. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.
Bracarda S; Altavilla A; Hamzaj A; Sisani M; Marrocolo F; Del Buono S; Danielli R
Semin Oncol; 2015 Jun; 42(3):495-505. PubMed ID: 25965369
[TBL] [Abstract][Full Text] [Related]
26. Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor.
Hwang I; Park I; Yoon SK; Lee JL
Asia Pac J Clin Oncol; 2022 Aug; 18(4):371-377. PubMed ID: 34219393
[TBL] [Abstract][Full Text] [Related]
27. Facing treatment of non-urothelial bladder cancers in the immunotherapy era.
Grilo I; Rodrigues C; Soares A; Grande E
Crit Rev Oncol Hematol; 2020 Sep; 153():103034. PubMed ID: 32622321
[TBL] [Abstract][Full Text] [Related]
28. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
Teo MY; Rosenberg JE
Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
[TBL] [Abstract][Full Text] [Related]
29. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
30. The immunotherapy revolution in genitourinary malignancies.
U Gandhy S; Madan RA; Aragon-Ching JB
Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
[TBL] [Abstract][Full Text] [Related]
31. Emerging therapeutic agents for genitourinary cancers.
Zarrabi K; Paroya A; Wu S
J Hematol Oncol; 2019 Sep; 12(1):89. PubMed ID: 31484560
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors in genitourinary malignancies.
Thana M; Wood L
Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
[TBL] [Abstract][Full Text] [Related]
34. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
Meza L; Malhotra J; Favorito C; Pal SK
Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Jang A; Adler DM; Rauterkus GP; Bilen MA; Barata PC
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680214
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Zhu J; Armstrong AJ; Friedlander TW; Kim W; Pal SK; George DJ; Zhang T
J Immunother Cancer; 2018 Jan; 6(1):4. PubMed ID: 29368638
[TBL] [Abstract][Full Text] [Related]
40. Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
